Speaking of SurgOnc

Rick Greene, MD, discusses with Anthony Villano, MD, a review the American College of Surgeons Commission on Cancer Standard 5.6, which pertains to curative intent colon resections performed for cancer. Dr. Villano is author of "Standardization of Colon Resection for Cancer: An Overview of the American College of Surgeons Commission on Cancer Standard 5.6." Dr. Villano is the Assistant Professor, Surgical Oncology, in the Department of Surgical Oncology, at Fox Chase Cancer Center in Philadelphia, PA.

Rick Greene, MD, discusses with Jean-Nicolas Vauthey, MD, a comparison of different surgical approaches to synchronous liver metastases from rectal cancer and their analysis of both clinicopathological and biological tumor factors associated with completion of the reverse approach. Professor Vauthey is the senior author of, “Hepatectomy Before Primary Tumor Resection as Preferred Approach for Synchronous Liver Metastases from Rectal Cancer.” Dr. Vauthey is Professor of Surgery and Chief of the Hepato-Pancreato-Biliary Section, and the Dallas/Fort Worth Living Legend Chair of Cancer Research in the Department of Surgical Oncology at The University of Texas MD Anderson Cancer Center in Houston, TX.

Rick Greene, MD, discusses with Patricio M. Polanco, MD, an analysis of three hospital designations, as well as volume status, and their effect on the delivery of care and survival outcomes using a cancer registry database of the second largest state in the USA. Dr. Polanco is co-corresponding author of, “Hospital Designations and Their Impact on Guideline-Concordant Care and Survival in Pancreatic Cancer. Do They Matter?.”

Rick Greene, MD, discusses with Eduardo A. Vega, MD, definitions reported on of benchmark values for gallbladder cancer surgery across an international population as well as geographic differences in gallbladder cancer surgery across multiple continents. Dr. Vega is the senior author of, “Benchmarks and Geographic Differences in Gallbladder Cancer Surgery: An International Multicenter Study.” Dr. Vega is Assistant Professor of Surgery at Boston University School of Medicine and Hepato-Bilio-Pancreatic surgeon in the Department of Surgery at St. Elizabeth’s Medical Center, Boston, MA. Full article: Benchmarks and Geographic Differences in Gallbladder Cancer Surgery: An International Multicenter Study | Annals of Surgical Oncology (springer.com)

Rick Greene, MD, discusses with Susan Tsai, MD, MHS, the results of an analysis examining the efficacy of second-line gemcitabine/nab-paclitaxel (GnP) after first-line FOLFIRINOX in the neoadjuvant setting among patients with operable pancreatic cancer who were treated with a total neoadjuvant approach. Dr. Tsai is the senior author of, “CA19-9 Response to First-line Neoadjuvant FOLFIRINOX and Second-line Gemcitabine/nab- Paclitaxel in Patients with Operable Pancreatic Cancer.” Dr. Tsai is Professor of Surgery and Chief of the Division of Surgical Oncology at The Ohio State University Comprehensive Cancer Center, Columbus, OH.

Rick Greene, MD, discusses with Sean Cleary, MD, cytoreductive hepatectomy for neuroendocrine tumor liver metastases; specifically, perioperative outcomes and operative trends, rates and duration of symptomatic relief, and long-term survival and predictors of prognosis. Dr. Cleary is the senior author of, “Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients.” Dr. Cleary is the Bernard and Ryna Langer Chair of the Division of General Surgery in the Department of Surgery at the University of Toronto, Toronto, Canada.

Rick Greene, MD, discusses with Anna Weiss, MD, the evidence-based treatments available for the adverse effects of endocrine therapy that can be experienced by breast cancer patients, including clear treatment algorithms for genitourinary syndrome of menopause (GSM), which can be overlooked by providers. Dr. Weiss is the senior author of, “Endocrine Therapy for Surgeons: Practical Pearls for Managing Menopausal, Bone Loss and Sexual Adverse Effects.” Dr. Weiss is Associate Professor of Surgery and Medicine, and Director of the Wilmot Cancer Institute Comprehensive Breast Cancer Program at Pluta, University of Rochester Medical Center, Rochester, NY.

Rick Greene, MD, and Tari King, MD, FSSO, discuss findings generated from central path review of a large series of patients treated with neoadjuvant chemotherapy and surgery regarding the pattern of residual tumor in the breast and its related prognostic significance. Dr. King is the senior author of, “Impact of the Histologic Pattern of Residual Tumor After Neoadjuvant Chemotherapy on Recurrence and Survival in Stage I–III Breast Cancer.” Dr. Tari A. King is the Anne E. Dyson Professor of Surgery at Harvard Medical School, the chief of the Division of Breast Surgery and the vice chair of multidisciplinary oncology in the Department of Surgery at Brigham and Women's Hospital, and the chief of breast surgery at Dana-Farber Brigham Cancer Center, Boston, Massachusetts.

Rick Greene, MD discusses with Edward A. Levine, MD, long-term survival in patients with malignant peritoneal mesothelioma undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Dr. Levine is the senior author of, “Long-Term Survival in Patients Treated with Cytoreduction and Heated Intraperitoneal Chemotherapy for Peritoneal Mesothelioma at a Single High-Volume Center.” Dr. Levine is Professor, Surgical Sciences - Oncology, Chief of Surgical Oncology at Atrium Wake Forest Health, and Section Editor of the Peritoneal Surface Malignancies section of the Annals of Surgical Oncology. https://link.springer.com/article/10.1245/s10434-022-13061-3

Rick Greene, MD, discusses with Jesse Selber MD, MPH, MHCM, FACS, the use of ChatGPT and explores questions regarding the potential of artificial intelligence (AI) in surgery and its opportunities, challenges, and possible role in surgery. Dr. Selber is the senior author of the article entitled "Exploring the Potential of Artificial Intelligence in Surgery: Insights from a Conversation with ChatGPT.” Dr. Selber is Surgical Service Line Chief and Professor of Plastic Surgery at Corewell Health, East outside of Detroit, Michigan. https://link.springer.com/article/10.1245/s10434-023-13347-0

Rick Greene, MD, discusses with Giammauro Berardi, MD, PhD, FEBS, the outcomes of a large cohort of patients undergoing upfront surgery for resectable colorectal liver metastases (CRLM) to analyze the predictability and probability of early treatment failure using clinicopathological characteristics. Dr. Berardi is author of, “A Model to Predict Treatment Failure in Patients Undergoing Upfront Surgery for Resectable Colorectal Liver Metastases.” Dr. Berardi is attending at the Department of HPB Surgery and Liver Transplantation of the San Camillo Forlanini Hospital, Rome, Italy, and previous to that was a Surgical Oncology clinical fellow at Memorial Sloan-Kettering Cancer Center, New York NY.

Rick Greene, MD, discusses with Julie Culver, MS, LCGC, CCRP, the implementation of genetic testing for all patients with breast cancer and how this can be incorporated into oncology care. Ms. Culver is author of “Integration of Universal Germline Genetic Testing for All New Breast Cancer Patients.” Julie Culver is the Director of Genetic Counseling at the USC Norris Cancer Hospital and is a Clinical Instructor of Medicine at the USC Keck School of Medicine, Los Angeles, CA. http://doi.org/10.1245/S10434-022-12595-W

Rick Greene, MD, discusses with Joel Baumgartner, MD, the rate of occult omental metastases in patients undergoing cytoreductive surgery-HIPEC for peritoneal surface malignancy. Dr. Baumgartner is author of, “Is Routine Omentectomy a Necessary Component of Cytoreductive Surgery and HIPEC?” Dr. Baumgartner is Associate Professor in the Department of Surgery, UC San Diego School of Medicine, San Diego, CA. http://doi.org/10.1245/S10434-022-12714-7

Rick Greene, MD, discusses with Margaret Kemeny, MD, the results of a phase III randomized trial that evaluated the effect of perioperative fluorouracil on overall survival in colon cancer. Dr. Kemeny is author of, "Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292)." Dr. Kemeny is Director of New York's Cancer Center of Excellence at Queens Cancer Center of NYC Health+Hospitals/Queens and Professor of Surgery at the Icahn School of Medicine at Mount Sinai. http://doi.org/10.1245/S10434-022-12705-8

Rick Greene, MD, discusses with Meghan R. Flanagan, MD, MPH, the results of a retrospective population-based study about genetic testing among patients with breast, ovarian, pancreatic and prostate cancers. Dr. Flanagan is author of, “Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers.” Dr. Flanagan is Assistant Professor of Surgery at the University of Washington School of Medicine, Seattle, WA. http://doi.org/10.1245/S10434-022-12755-Y

Rick Greene, MD, and Audree Tadros, MD, MPH, FACS, discuss the BREAST-Q, a validated patient-reported outcome measure for satisfaction and quality of life after breast surgery, to determine whether patient satisfaction and quality of life differs among T4 breast cancer patients based on their decision to pursue reconstruction and the timing of reconstruction. Dr. Tadros is author of “Patient-Reported Outcome Measures in Patients with Clinical T4 Breast Cancer Treated with Mastectomy with and without Reconstruction.” Dr. Audree Tadros is the Jeanne A. Petrek Junior Faculty Chair, Memorial Sloan-Kettering Cancer Center, New York, and Assistant Attending Surgeon, Memorial Sloan-Kettering Cancer Center, New York, NY.

Rick Greene, MD, discusses with Joon Park, MD, the national implementation patterns and perioperative outcomes of minimally invasive gastrectomy in gastric cancer surgery in the US. Dr. Park is author of “Disparities in Utilization and Outcomes of Minimally Invasive Techniques for Gastric Cancer Surgery in the United States.” Dr. Joon Park is a Resident of Surgery in the Department of Surgery, UCLA David Geffen School of Medicine, Los Angeles, CA.

Dr. Rick Greene and Dr. Fadi Dahdaleh discuss the effect of operative approach on overall readiness to commence adjuvant therapy in patients with pancreatic ductal adenocarcinoma undergoing pancreaticoduodenectomy, hypothesizing that minimally invasive pancreaticoduodenectomy improves rates and time to return to intended oncologic therapy compared with open pancreaticoduodenectomy. Dr. Dahdaleh is author of “Surgical Approach does not Affect Return to Intended Oncologic Therapy Following Pancreaticoduodenectomy for Pancreatic Adenocarcinoma: A Propensity-Matched Study.” Dr. Dahdaleh is an attending surgical oncologist at Northshore-Edward-Elmhurst Health in Chicago and adjunct clinical assistant professor of surgery at Rush Medical College, Chicago, IL.

In this episode of SurgOnc Today®, Laurence McCahill, MD, of Western Michigan University is joined by Julie Barone, DO, Medical Director of Vail Comprehensive Breast Care and John Abad, MD, of Northwestern Medicine Regional Medical Group. They discuss their personal pathways that brought them into leadership roles within the community care practice setting, including their experiences with the accreditation of their programs, the establishment of their research programs and the use of their...

Rick Greene, MD, discusses with Anne O’Shea, MD, and Timothy Vreeland, MD, the role of neoadjuvant chemotherapy or chemoradiation in the treatment of localized pancreatic adenocarcinoma, and the effect of downstaging on overall survival. Dr. O’Shea and Dr. Vreeland are authors of “Downstaging of Pancreatic Adenocarcinoma with Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival.” Dr. Anne O’Shea is Resident of Surgery in the Department of Surgery at Brooke Army Medical Center, Ft. Sam, San Antonio, TX. Dr. Timothy Vreeland is a Surgical Oncologist also at the Brooke Army Medical Center, Ft. Sam, San Antonio, TX.